6:06 PM
 | 
Feb 04, 2014
 |  BC Extra  |  Clinical News

Furiex skyrockets on Phase III IBS-D data

Furiex Pharmaceuticals Inc. (NASDAQ:FURX) jumped $59.72 (130%) to $105.69 on Tuesday after reporting that twice-daily 100 mg oral eluxadoline met both the FDA-defined and EMA-defined primary endpoint in a pair of double-blind, international Phase III trials to treat diarrhea-predominant...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >